Related Experiment Video
Updated: Apr 27, 2026
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Neuroprotective therapies after perinatal hypoxic-ischemic brain injury
Felipe Goñi de Cerio1, Idoia Lara-Celador2, Antonia Alvarez3
1Biotechnology Area, GAIKER Technology Centre, Parque Tecnológico de Zamudio Ed 202, 48170 Zamudio, Vizcaya, Spain. goni@gaiker.es.
Insights
Hypoxic-ischemic (HI) brain injury in newborns causes significant disability. Effective therapies are needed to reduce brain damage and promote neuronal regeneration.
Area of Science:
- Neonatal neurology
- Neuroscience
- Pediatric critical care
Background:
- Hypoxic-ischemic (HI) brain injury is a leading cause of disability in term-born infants, resulting from oxygen and glucose deprivation.
- Neonatal HI is a critical condition with potential for long-term neurological deficits or mortality.
- HI injury progresses in two phases: primary energy failure and a secondary phase hours later, leading to cognitive and motor impairments.
Purpose of the Study:
- To address the urgent need for effective therapies to mitigate neonatal brain damage from HI injury.
- To explore therapeutic strategies targeting different stages and mechanisms of HI-induced brain injury.
- To identify opportunities for promoting neurotrophic properties for neuronal and oligodendrocyte regeneration.
Main Methods:
- Review of existing literature on HI brain injury mechanisms and therapeutic approaches.
- Analysis of therapeutic strategies including antioxidant, anti-inflammatory, and anti-apoptotic interventions.
- Exploration of neurotrophic factor-based therapies for promoting neural repair.
Main Results:
- HI injury involves a biphasic energy failure impacting neural tissue.
- Therapeutic interventions aim to prevent reactive oxygen species, reduce inflammation, and inhibit apoptosis.
- Later-stage interventions focus on stimulating neurotrophic factors for regeneration.
Conclusions:
- Early diagnosis and treatment of neonatal HI injury remain challenging, necessitating novel therapeutic approaches.
- A multi-faceted therapeutic strategy targeting both acute injury and long-term regeneration is crucial.
- Stimulating neurotrophic properties holds promise for improving outcomes in HI-affected neonates.
Abstract:
Hypoxic-ischemic (HI) brain injury is one of the main causes of disabilities in term-born infants. It is the result of a deprivation of oxygen and glucose in the neural tissue. As one of the most important causes of brain damage in the newborn period, the neonatal HI event is a devastating condition that can lead to long-term neurological deficits or even death. The pattern of this injury occurs in two phases, the first one is a primary energy failure related to the HI event and the second phase is an energy failure that takes place some hours later. Injuries that occur in response to these events are often manifested as severe cognitive and motor disturbances over time. Due to difficulties regarding the early diagnosis and treatment of HI injury, there is an increasing need to find effective therapies as new opportunities for the reduction of brain damage and its long term effects. Some of these therapies are focused on prevention of the production of reactive oxygen species, anti-inflammatory effects, anti-apoptotic interventions and in a later stage, the stimulation of neurotrophic properties in the neonatal brain which could be targeted to promote neuronal and oligodendrocyte regeneration.
